Seattle Genetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SGEN Nasdaq 8731 http://www.seattlegenetics.com/ 63.86 Stock Down -0.15

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Seattle Genetics, Inc.

See what the IHS Markit Score report has to say about Seattle Genetics Inc. - Oct 19th, 2017 6:06 am
Cramer’s Exec Cut: CEO reveals his company’s plans to dis... - Oct 13th, 2017 5:13 pm
Cancer Space Update: Lung & Breast Cancer Studies in Focus - Oct 13th, 2017 9:18 am
Seattle Genetics Inks Clinical Collaborations for Cancer Drug - Oct 12th, 2017 8:18 am
Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics - Oct 12th, 2017 6:20 am
Cramer Remix: It’s not about sex appeal, it’s about timin... - Oct 11th, 2017 5:10 pm
Seattle Genetics CEO talks new cancer treatment pipeline,... - Oct 11th, 2017 5:02 pm
Cramer Remix: It’s not about sex appeal, it’s about timing - Oct 11th, 2017 4:59 pm
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today - Oct 11th, 2017 3:03 pm
This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck - Oct 11th, 2017 2:38 pm
Seattle Genetics Begins Phase II Study of Cancer Candidate - Oct 11th, 2017 8:29 am
Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer - Oct 11th, 2017 6:00 am
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer - Oct 10th, 2017 6:00 am
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer - Oct 10th, 2017 6:00 am
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer - Oct 10th, 2017 4:44 am
Cancer Space Last Week Update: Pipeline Expansion in Focus - Oct 9th, 2017 8:13 am
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017 - Oct 5th, 2017 6:00 am
Cramer's lightning round: Why my charitable trust sold it... - Oct 4th, 2017 5:03 pm